Oncological issues are becoming more and more burdensome on many people, but there’s a speck of light at the end of the tunnel.

In a time when millions of people are battling serious cancer conditions, Ron Bentsur, a highly experienced biotechnologist, offers a helping hand to possibly save millions.

Ron founded Nuvectis Pharma - a modern and well-equipped company that aims towards remarkable changes and progress in the field of medicine.

Nuvectis Pharma Inc. focuses on designing therapies for treating cancer, which restores hope for many patients. As a new biopharmaceutical company that is implementing innovative precision medicines, finding essential measurements for severe oncology conditions is a foremost priority.

But, who is Ron Bentsur? Stay with us and read on about the people on Ron’s team, and Nuvectis Pharma, the biopharmaceutical company changing the way we treat cancer.

In Constant Search of the Unseen

Ron Bentsur, the founder of Nuvectis Pharma, was born in 1965, to a loving Israeli family. Growing up, Ron had always been interested in exploring the outdoors.

As time passed by, Ron shifted interests and became curious about business, and decided to pursue his career as a businessman.

Being a bookwork, Ron graduated Economics and Business Administration at the Hebrew University of Jerusalem, in Israel, and, he’s also a proud owner of a Magna Cum Laude from New York University.

Being an experienced biotechnological magnate for more than 20 years, Ron has served as CEO of UroGen Pharma Inc. in the period between 2015 and 2019. Not stopping there, Ron had also been appointed CEO of Keryx Biopharmaceuticals Inc. for 6 years, from 2009 until 2015. At Keryx and UroGen, Ron ran the regulatory approvals, clinical development, and the commercial organization build-outs for the US profitable promotions of prescription drugs Jelmyto and Auryxia.

He was the CEO of XTL Biopharmaceuticals Inc. from 2006 until 2009. Being highly motivated, switching positions and companies was a regular occurrence for Ron, as he wanted to explore as many opportunities as possible.

The Dream Team behind Nuvectis Pharma

Nuvectis Pharma is proud to have attained such a strong management team, and except Ron Bentsur, Enrique Poradosu, and Shay Shemesh support the development of remedies for treating cancer.

Enrique Poradosu, is Executive Vice President, Business Officer, and Chief Scientific in Nuvectis Pharma. He has over 20 years of scientific management experience in the prominent biotechnology industry.

Enrique was a part of Stemline Therapeutics Inc. from 2016 to 2020, leading the certifying and scientific strategy of the Stemline Company’s pipeline, being in charge of strategic planning and testing of the initial-stage medication development programs.

Dr. Enrique also worked for Keryx Biopharmaceuticals Inc. as VP of Business and Scientific Strategy from 2003 to 2016. He holds a BSc in Chemistry and Biology, and a Ph.D. in Biochemistry from the Hebrew University of Jerusalem, Israel.

Shay Shemesh, the last member of Ron’s dream team is an executive Vice President and Chief Development Officer in Nuvectis. He boasts over 14 years of experience in developing drugs.

From 2015 until 2020, Shay was part of Stemline Therapeutics Inc. where he led integrative development teams in both initial-stage and late-stage projects. Before that, Shay managed the last-stage scientific trials for the anemia treatment in patients with non-dialysis CKD, at Keryx Biopharmaceutical. He holds a Bachelor of Science and Masters of Science in Biotechnology from Bar Ilan University, Israel. A partnership of these 3 prominent names makes Nuvectis Pharma a promising company with a unique dream team.

All About Nuvectis Pharma

Founded in 2020, Nuvectis holds offices in Fort Lee, New Jersey, United States.

Driven by the thought that the world needs effective therapy for oncological conditions and that people deserve to live life without pain, Ron Bentsur started Nuvectis Pharma.

The company’s main focus is to develop innovative medicines for treating serious oncological illnesses. Currently, Nuvectis Pharma is developing 2 unique precision-medicine remedy candidates that can fight cancer.

A year after the company was brought to light, in May 2021, Nuvectis approved exclusive global commercial rights to the revolutionary NXP800. It is an HSF1 pathway inhibitor, which was founded and developed in the special drug detection program at the prestigious Institute for Cancer Research in London, England.

Wanting to land a breakthrough in the suffering world of cancer-battling, Nuvectis Pharma did the almost unimaginable when it brought pathway inhibitors closer to patients in dire need.

In August of 2021, Nuvectis bought the exclusive global rights to NXP900 - an innovative small-molecule remedy that was developed by the highly reputable University of Edinburgh.

NXP800's initial target is progressive OCCC (ovarian clear cell carcinoma) and refractory/relapsed endometrial ovarian cancer. NXP900 is a preclinical drug candidate, whose target is severe tumors such as ovarian, prostate, colon, breast, and pancreatic cancers. Nuvectis tests a remedy that will successfully fight different oncological conditions but will remain mainly inactive in non-cancerous cells.

The CEO at Nuvectis reveals that they plan to introduce NXP800 as a cure for endometrioid ovarian cancer and ovarian clear cell cancer.

Knowing that OCCC is intensely malignant, hard to treat, and is attached to a terribly low survival rate because of frequent reappearance after surgery and after the initial treatment, the NXP800 is truly a blessing.

The popular first-line medical treatment covers platinum-based chemotherapy, but it is clear that medicine needs a fully new treatment alternative for OCCC.

Securing the Finances

Nuvectis Pharma, a developer of pretrial therapy for cancer treatments, is worth around $30million, with its shares ranging between $12 and $14.

More precisely, Nuvectis expects to raise $30M net income by offering 2.3M shares at a suggested mid-price of $13.00 per share. The market capitalization of Nuvectis Pharma is estimated at $160M. The company licensed global rights for NXP800 and the second phase of treatment, NXP900, and received $15M financing for NXP800.

Before doing an IPO, Nuvectis Pharma managed to raise $15.3M through a venture series by an unknown investor.

The company is utterly proud of its NXP800 since it holds massive potential, possibly offering a broad spectrum of uses, including urothelial, oesophageal, hepatocellular, and gastric carcinoma among the others, though it will probably focus mainly on ovarian cancer types. That tracks with Nuvectis's stated goal of addressing unmet patient markets as well as filling intermediate medical spaces.

Stirring the Murky Waters of Cancer Issues

The prospects of Nuvectis may depend on the up-and-coming finishing point and commercial launch of the two current drug candidates, but we can’t be sure about that as there is no guarantee for that.

Since cancer research is an extremely promising zone, the oncology pharmaceutical market is vastly competitive. Rival companies like Constellation Pharma, Immunogen Therapeutics, and Turning Point Therapeutics among others, have only strengthened Nuvectis Pharma’s drive to succeed.

Nuvectis Pharms is a phase-I ready company, but its formulations must complete the phase-II trials before showing up at the market. The development activities and intense research related to clinical programs are expected to require some serious investments.

Nuvectis management has a great plan on how to use the gross proceeds from the IPO. The company strives to increase its capitalization as well as financial flexibility and create a stable public market for its common stock.

In that way, it will connect to the public fair markets for itself and its stockholders. Nuvectis Pharma expects to use the gross proceeds from this proposal to fund the approval for conducting human clinical traits for NXP900 and to fund Phase 1/2 development of NXP800. The team also plans to continue improvement and sponsored research associated with their ongoing product candidates or upcoming product candidates, capital expenditures, hiring of additional personnel, expenses of working as a public company, and similar general corporate purposes.

Today, being headquartered in New Jersey and employing around 6 people, Nuvectis Pharma is still led forward by Ron Bentsur as the CEO. Looking to expand the market with a number of ground-breaking remedies for battling cancer, Nuvectis Farma is doing its best in providing patients with paramount remedies.